Literature DB >> 1280804

Alterations in neuronal excitability and the potency of spinal mu, delta and kappa opioids after carrageenan-induced inflammation.

L C Stanfa1, A F Sullivan, A H Dickenson.   

Abstract

These electrophysiological results show that the development of inflammation following peripheral injection of carrageenan into the paw is accompanied by alterations in the magnitude of the C-fibre evoked response of multireceptive dorsal horn neurones. The evoked response of the dorsal horn cells was found to either increase or decrease in the 3 h following the carrageenan injection, and the direction of this change was related to the degree of wind-up exhibited by the cell. Regardless of whether a cell was facilitated or inhibited by carrageenan, mu, delta and kappa opioids applied topically onto the spinal cord (equivalent to an intrathecal injection) exhibited increased antinociceptive potency. This increased effectiveness was especially marked for the mu opioid, morphine, which showed a 30-fold increase in potency. Interestingly the facilitations seen with the lowest doses of the mu and kappa opioids in this model in normal animals were absent after carrageenan. In addition, a very low dose of spinal naloxone caused a small but significant reduction in the C-fibre evoked responses. These results demonstrate that following peripheral inflammation, functional changes develop in both spinal transmission and modulatory systems. Alterations in the antinociceptive potency of opioid agonists occurs, with the mu agonist, morphine, showing the greatest change.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280804     DOI: 10.1016/0304-3959(92)90040-i

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  22 in total

1.  Poster communications.

Authors: 
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

2.  Spinal and peripheral mechanisms involved in the enhancement of morphine analgesia in acutely inflamed mice.

Authors:  Sara González-Rodríguez; Agustín Hidalgo; Ana Baamonde; Luis Menéndez
Journal:  Cell Mol Neurobiol       Date:  2009-08-05       Impact factor: 5.046

Review 3.  The postnatal development of spinal sensory processing.

Authors:  M Fitzgerald; E Jennings
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

4.  Electrophysiological studies on the postnatal development of the spinal antinociceptive effects of the delta opioid receptor agonist DPDPE in the rat.

Authors:  W Rahman; A H Dickenson
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 5.  Spinal opioid systems in inflammation.

Authors:  L Stanfa; A Dickenson
Journal:  Inflamm Res       Date:  1995-06       Impact factor: 4.575

6.  Dynamic temporal and spatial regulation of mu opioid receptor expression in primary afferent neurons following spinal nerve injury.

Authors:  Chun-Yi Lee; Federico M Perez; Wei Wang; Xiaowei Guan; Xiuli Zhao; Janet L Fisher; Yun Guan; Sarah M Sweitzer; Srinivasa N Raja; Yuan-Xiang Tao
Journal:  Eur J Pain       Date:  2011-02-09       Impact factor: 3.931

7.  Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain.

Authors:  Devki D Sukhtankar; Heeseung Lee; Kenner C Rice; Mei-Chuan Ko
Journal:  Psychopharmacology (Berl)       Date:  2013-11-12       Impact factor: 4.530

8.  Cholecystokinin as a factor in the enhanced potency of spinal morphine following carrageenin inflammation.

Authors:  L C Stanfa; A H Dickenson
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

9.  Effect of CCK receptor antagonists on the antinociceptive, reinforcing and gut motility properties of morphine.

Authors:  L Singh; R J Oles; M J Field; P Atwal; G N Woodruff; J C Hunter
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

10.  The roles of nerve growth factor and cholecystokinin in the enhancement of morphine analgesia in a rodent model of central nervous system inflammation.

Authors:  Dimitris N Xanthos; Naresh Kumar; Elvar Theodorsson; Terence J Coderre
Journal:  Neuropharmacology       Date:  2008-12-11       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.